Stay updated on Gantenerumab Long-term Safety in AD Clinical Trial
Sign up to get notified when there's something new on the Gantenerumab Long-term Safety in AD Clinical Trial page.

Latest updates to the Gantenerumab Long-term Safety in AD Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedLocations section expanded to include new regional sites across the US and internationally (Arizona, California, Florida, Michigan, New York, North Carolina, Oklahoma, Tennessee, Texas, South Australia, Victoria, Nova Scotia, Ontario, Emilia-Romagna, Lombardy, Mexico City, Nuevo León, Sankt-Peterburg, Alicante, Barcelona) and updated to v3.3.3; some previous location groupings were removed.SummaryDifference2%

- Check21 days agoNo Change Detected
- Check29 days agoNo Change Detected
- Check43 days agoChange DetectedThe page shows a new revision label 'Revision: v3.3.2' in place of the previous 'Revision: v3.2.0'. This looks like a frontend update and does not modify study details or other substantive content.SummaryDifference0.0%

- Check50 days agoChange DetectedRemoved the top banner notice about government funding and operating status, which does not affect the study data or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check64 days agoChange DetectedThe ClinicalTrials.gov record now indicates termination of the study of gantenerumab for Alzheimer's disease following a pre-planned analysis. This update changes the study status and completion information shown on the page.SummaryDifference0.3%

- Check93 days agoChange DetectedSignificant update: new operating-status notice and version bump to v3.2.0; previous v3.1.0 tag removed. Core content impacted by the new status information.SummaryDifference3%

- Check100 days agoChange DetectedVersion updated from v3.0.2 to v3.1.0; no other substantive content changes detected.SummaryDifference0.1%

Stay in the know with updates to Gantenerumab Long-term Safety in AD Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Gantenerumab Long-term Safety in AD Clinical Trial page.